First in Human, Dose Escalation, Dose Expansion Study of AUR105 (SURYA-1)
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR105 in Patients With Relapsed Advanced Malignancies (SURYA-1)
Sponsor: Aurigene Discovery Technologies Limited
Terminated
Patient recruitment problems.
Other terminated trials from Aurigene Discovery Technologies Limited
- Advanced Malignant Neoplasm · Feb 2026
- Select Relapsed/Refractory Lymphoid Malignancies · Feb 2026
- Colorectal Cancer · Feb 2026
- Gastroesophageal Junction Adenocarcinoma · Dec 2025
- Acute Myeloid Leukemia · Nov 2024
More terminations from Aurigene Discovery Technologies Limited
This observational or N/A phase trial investigates Hodgkin Lymphoma and Non-hodgkin Lymphoma and is currently terminated or withdrawn. Aurigene Discovery Technologies Limited leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)This is a Phase I, Open label First in Human Study in adult patients with relapsed advanced malignancies.
The study will have two parts. Dose escalation part and Dose expansion part
This is a Phase I, Open label First in Human Study in adult patients with relapsed advanced malignancies.
The study will have two parts. Dose escalation part and Dose expansion part
Status Flow
Change History
6 versions recorded-
Apr 18, 2026 — Present [daily]
Terminated
Status: Recruiting → Terminated · Phase: PHASE1 → None
-
Sep 2024 — Apr 2026 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jan 2023 — Feb 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Dec 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies. The study will have two parts: a Dose Escalation Part and Dose Expansion Part.
Contact Information
- Aurigene Discovery Technologies Limited
For direct contact, visit the study record on ClinicalTrials.gov .